About Cytoskeleton-associated protein 2-like
Cytoskeleton-associated protein 2-like (CKAP2L) is a protein
from Homo sapiens identified by UniProt accession
Q8IYA6, 745 residues long.
MolForge cross-references it against 0 known binders and
63 disease associations.
Target properties
| Protein name | Cytoskeleton-associated protein 2-like |
|---|
| UniProt accession | Q8IYA6 |
|---|
| Gene | CKAP2L |
|---|
| Organism | Homo sapiens |
|---|
| Length | 745 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8IYA6-F1 | alphafold | PREDICTED | 54.29 | — |
Amino-acid sequence (745 residues)
MVGPGPTAAA AVEERQRKLQ EYLAAKGKLK SQNTKPYLKS KNNCQNQPPS KSTIRPKNDV TNHVVLPVKP KRSISIKLQP RPPNTAGSQK PKLEPPKLLG KRLTSECVSS NPYSKPSSKS FQQCEAGSST TGELSRKPVG SLNIEQLKTT KQQLTDQGNG KCIDFMNNIH VENESLDNFL KETNKENLLD ILTEPERKPD PKLYTRSKPK TDSYNQTKNS LVPKQALGKS SVNSAVLKDR VNKQFVGETQ SRTFPVKSQQ LSRGADLARP GVKPSRTVPS HFIRTLSKVQ SSKKPVVKNI KDIKVNRSQY ERPNETKIRS YPVTEQRVKH TKPRTYPSLL QGEYNNRHPN IKQDQKSSQV CIPQTSCVLQ KSKAISQRPN LTVGRFNSAI PSTPSIRPNG TSGNKHNNNG FQQKAQTLDS KLKKAVPQNH FLNKTAPKTQ ADVTTVNGTQ TNPNIKKKAT AEDRRKQLEE WQKSKGKTYK RPPMELKTKR KVIKEMNISF WKSIEKEEEE KKAQLELSSK INNTLTECLN LIEGGVPSNE ILNILSSIPE AEKFAKFWIC KAKLLASKGT FDVIGLYEEA IKNGATPIQE LRKVVLNILQ DSNRTTEGIT SDSLVAETSI TSVEELAKKM ESVKSCLSPK EREQVTATPR IAKAEQHNYP GIKLQIGPIP RINGMPEVQD MKFITPVRRS SRIERAVSRY PEMLQEHDLV VASLDELLEV EETKCFIFRR NEALPVTLGF QTPES
Explore Cytoskeleton-associated protein 2-like with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets